From the perspective of a lipid specialist, especially in light of the associated all-cause mortality reductions reported in ODYSSEY Outcomes, how should the clinician be thinking about PCSK9 inhibitors as a tool in their day-to-day practice?

Name: From the perspective of a lipid specialist, especially in light of the associated all-cause mortality reductions reported in ODYSSEY Outcomes, how should the clinician be thinking about PCSK9 inhibitors as a tool in their day-to-day practice?
Uploaded: 2019-03-11T00:00:00+00:00

CLICK HERE FOR CME CREDIT

Created by

Presenter

Erik S.G Stroes, MD, PhD

Professor
Department of Vascular Medicine
Academic Medical Center
Amsterdam, The Netherlands